The RECELL System is approved for the treatment of burn wounds and full-thickness skin defects, and for re-pigmentation of stable depigmented vitiligo lesions. RECELL harnesses the regenerative properties of a patient’s own skin to create Spray-On Skin™ cells, delivering a transformative solution at the point-of-care. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes.
Expedite the healing process with early treatment at a cellular level
The power of multi-phenotype Spray-On Skin Cells.
Autologous therapy at point-of-care allows for delivery of the patient’s own living cells:
1. Wood FM, Giles N, Stevenson A, Rea S, Fear M. Characterisation of the cell suspension harvested from the dermal epidermal junction using a ReCell® kit. Burns. Published online November 12, 2011. doi:10.1016/ j.Burns.2011.03.001.
2. Navarro FA, Stoner ML, Lee HB, et al. Melanocyte repopulation in full-thickness wounds using a cell spray apparatus. J Burn Care Rehabil 2001;22:41–6.
3. Navarro FA, Stoner ML, Park CS, et al. Sprayed keratinocyte suspensions accelerate epidermal coverage in a porcine microwound model. J Burn Care Rehabil 2000;21:513–8.
4. Freedberg I, Tomic-Canic M, Komine M, et al. Keratins and the Keratinocyte Activation Cycle J Invest Dermatol 116:633-640, 2001.
5. Hirobe T. Keratinocytes regulate the function of melanocytes. Dermatol Sin. 2014;32(4):200-204.
4. Freedberg I, Tomic-Canic M, Komine M, et al. Keratins and the Keratinocyte Activation Cycle J Invest Dermatol 116:633-640, 2001.
5. Hirobe T. Keratinocytes regulate the function of melanocytes. Dermatol Sin. 2014;32(4):200-204.
Caring for your patients means more than closing the wound.
With RECELL, you can expedite the healing process with early point-of-care treatment of burn wounds and full-thickness skin defects providing the best possible outcomes for patients. Designed for donor sparing, significantly less donor skin is required with similar healing outcomes versus conventional autografting.
Cost-effective point-of-care regenerative therapy in a single procedure[8,9]
6. Holmes JH, Molnar JA, Carter JE, et al. A comparative study of the RECELL® device and autologous split-thickness meshed skin graft in the treatment of acute burn injuries. J Burn Care Res.2018 Aug 17;39(5):694-702.
7. Holmes JH, Molnar JA, Shupp JW, et al. Demonstration of the safety and effectiveness of the RECELL® system combined with split-thickness meshed autografts for the reduction of donor skin to treat mixed-depth burn injuries. Burns.2019;45(4):772-782. Care Res. 2018;39(5):694-702.
8. Instructions for Use. RECELL® Autologous Cell Harvesting Device.
8. Instructions for Use. RECELL® Autologous Cell Harvesting Device.
9. Kowal S, Kruger E, Bilir P, et al. Cost effectiveness of the use of autologous cell harvesting device compared to standard of care for treatment of severe burns in the United States. Adv Ther.Published online May 7, 2019. doi: 10.1007/s12325-019-00961-2.
9. Kowal S, Kruger E, Bilir P, et al. Cost effectiveness of the use of autologous cell harvesting device compared to standard of care for treatment of severe burns in the United States. Adv Ther.Published online May 7, 2019. doi: 10.1007/s12325-019-00961-2.
9. Kowal S, Kruger E, Bilir P, et al. Cost effectiveness of the use of autologous cell harvesting device compared to standard of care for treatment of severe burns in the United States. Adv Ther.Published online May 7, 2019. doi: 10.1007/s12325-019-00961-2.
10. Foster K, Bilir P, Kruger E, et al. Cost-effectiveness of RECELL® Autologous Cell Harvesting Device (ACHD) versus STSG for treatment of severe burns in the United States. Presented at the American Burn Association 2018 Annual Meeting, April 2018.
11. Carter JE, Carson JS, Hickerson WL, et al. Length of Stay and Costs with Autologous Skin Cell Suspension Versus Split-Thickness Skin Grafts: Burn Care Data from US Centers [published online ahead of print, 2022 Sep 14]. Adv Ther.2022;10.1007/s12325-022-02306-y. doi :10.1007/s12325-022-02306-y.
12. Carson JS, Carter JE, Hickerson WL, et al. Analysis of real-world length of stay data and costs associated with use of autologous skin cell suspension for the treatment of small burns in U.S. centers [published online ahead of print, 2022 Dec 5]. Burns. 2022; S0305-4179(22)00299-6. doi: 10.1016/j. burns.2022.11.007.
AUSTRALIA
Revolution Surgical Pty Ltd
4/22 Rowood Road, Prospect NSW 2148
ABN: 63 165 643 434
NEW ZEALAND
Revolution Surgical New Zealand Ltd
378 Neilson Street, Penrose Auckland 1061 New Zealand
NZBN: 145-925-924
© 2018- Revolution Surgical